• Legislative proposals related to prompt pay discounts for drugs and biologicals under Medicare Part B, including S. 733 and H.R. 905; federal policy regarding proposed changes to Medicare drug reimbursement average sales price (ASP) formula; ASP generally (in the context of Deficit Reduction).
• Legislative proposals to amend the Internal Revenue Code, provisions related to the last-in-first-out inventory accounting method, including the President's proposed FY 2013 budget, S. 89, and S. 164.
• Legislative proposals related to pharmaceutical pedigree anti-counterfeiting, wholesale transaction documentation, and electronic tracking, including H.R. 1483, H.R. 3026, and S. 1584; legislative proposals related to drug shortages, including H.R. 2245 and S. 296.

Duration: March 1, 2010 to January 31, 2013

General Issues: Medicare/Medicaid, Taxation/Internal Revenue Code, Pharmacy

Spending: about $490,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2010: House of Representatives, U.S. Senate, House of Representatives,, Food & Drug Administration (FDA)

Affiliated organizations: Dow Lohnes PLLC; ; n/a